These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31841646)

  • 61. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D; Wigal S; Swanson J; Hirsch S; Ottolini Y; Dariani M; Roffman M; Zeldis J; Cooper T
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder.
    Golubchik P; Rapaport M; Weizman A
    Int Clin Psychopharmacol; 2017 Sep; 32(5):289-293. PubMed ID: 28368900
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Differential stimulant response on attention in children with comorbid anxiety and oppositional defiant disorder.
    Goez H; Back-Bennet O; Zelnik N
    J Child Neurol; 2007 May; 22(5):538-42. PubMed ID: 17690058
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms.
    Marchant BK; Reimherr FW; Robison RJ; Olsen JL; Kondo DG
    J Atten Disord; 2011 May; 15(4):295-304. PubMed ID: 20410322
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder.
    Manos MJ; Short EJ; Findling RL
    J Am Acad Child Adolesc Psychiatry; 1999 Jul; 38(7):813-9. PubMed ID: 10405498
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder.
    Gadow KD; Sverd J; Nolan EE; Sprafkin J; Schneider J
    J Am Acad Child Adolesc Psychiatry; 2007 Jul; 46(7):840-8. PubMed ID: 17581448
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Gnagy EM; Chronis AM; Burrows-MacLean L; Fabiano GA; Onyango AN; Meichenbaum DL; Williams A; Aronoff HR; Steiner RL
    Pediatrics; 1999 Dec; 104(6):1300-11. PubMed ID: 10585981
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Effectiveness and Tolerability of Central Nervous System Stimulants in School-Age Children with Attention-Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Across Home and School.
    Baweja R; Belin PJ; Humphrey HH; Babocsai L; Pariseau ME; Waschbusch DA; Hoffman MT; Akinnusi OO; Haak JL; Pelham WE; Waxmonsky JG
    J Child Adolesc Psychopharmacol; 2016 Mar; 26(2):154-63. PubMed ID: 26771437
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Mixed Opioid Receptor Antagonist Naltrexone Mitigates Stimulant-Induced Euphoria: A Double-Blind, Placebo-Controlled Trial of Naltrexone.
    Spencer TJ; Bhide P; Zhu J; Faraone SV; Fitzgerald M; Yule AM; Uchida M; Spencer AE; Hall AM; Koster AJ; Feinberg L; Kassabian S; Storch B; Biederman J
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29617066
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder.
    Szobot CM; Rohde LA; Katz B; Ruaro P; Schaefer T; Walcher M; Bukstein O; Pechansky F
    Braz J Med Biol Res; 2008 Mar; 41(3):250-7. PubMed ID: 18327433
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Testicular Function After Long-Term Methylphenidate Treatment in Boys with Attention-Deficit/Hyperactivity Disorder.
    Wang LJ; Lee SY; Chou WJ; Lee MJ; Tsai CS; Lee TL; Yang CJ; Yang KC; Chen CK; Shyu YC
    J Child Adolesc Psychopharmacol; 2019 Aug; 29(6):433-438. PubMed ID: 30575416
    [No Abstract]   [Full Text] [Related]  

  • 74. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders.
    Abikoff H; McGough J; Vitiello B; McCracken J; Davies M; Walkup J; Riddle M; Oatis M; Greenhill L; Skrobala A; March J; Gammon P; Robinson J; Lazell R; McMahon DJ; Ritz L;
    J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):418-27. PubMed ID: 15843763
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit/hyperactivity disorder in intellectually capable adults with autism spectrum disorder.
    Joshi G; DiSalvo M; Wozniak J; Ceranoglu TA; Yule A; Surman C; Fried R; Galdo M; Hoskova B; Belser A; Biederman J
    World J Biol Psychiatry; 2020 Apr; 21(4):274-290. PubMed ID: 31607204
    [No Abstract]   [Full Text] [Related]  

  • 76. Telephone-assisted self-help for parents of children with attention-deficit/hyperactivity disorder who have residual functional impairment despite methylphenidate treatment: a randomized controlled trial.
    Dose C; Hautmann C; Buerger M; Schuermann S; Woitecki K; Doepfner M
    J Child Psychol Psychiatry; 2017 Jun; 58(6):682-690. PubMed ID: 27878809
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.
    Handen BL; Johnson CR; Lubetsky M
    J Autism Dev Disord; 2000 Jun; 30(3):245-55. PubMed ID: 11055460
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of methylphenidate on three forms of response inhibition in boys with AD/HD.
    Scheres A; Oosterlaan J; Swanson J; Morein-Zamir S; Meiran N; Schut H; Vlasveld L; Sergeant JA
    J Abnorm Child Psychol; 2003 Feb; 31(1):105-20. PubMed ID: 12597703
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood?
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2013; 36(5):141-5. PubMed ID: 24045603
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder.
    Bouffard R; Hechtman L; Minde K; Iaboni-Kassab F
    Can J Psychiatry; 2003 Sep; 48(8):546-54. PubMed ID: 14574830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.